Effect of Jianpi Qinghua Sanyu Drink on REG with Spleen Deficiency, Dampness, Heat and Blood Stasis Syndrome by Inhibiting NLRC4/caspase-1/IL-1β Signal Pathway

2021 ◽  
Vol 11 (10) ◽  
pp. 4808-4816
Author(s):  
培琳 赵
Keyword(s):  
Blood Stasis ◽  
Signal Pathway ◽  
Blood Stasis Syndrome ◽  
Spleen Deficiency ◽  
Caspase 1

scholarly journals Serum MicroRNA Profiling and Bioinformatics of Patients with Spleen-Deficiency Syndrome

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Ze-Min Yang ◽  
Long-Hui Chen ◽  
Min Hong ◽  
Ying-Yu Chen ◽  
Xiao-Rong Yang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Stasis ◽  
Deficiency Syndrome ◽  
Blood Stasis Syndrome ◽  
Syndrome Differentiation ◽  
Kegg Pathways ◽  
Spleen Deficiency ◽  
Serum Microrna ◽  
Molecular Functions ◽  
Spleen Deficiency Syndrome

To investigate serum microRNA (miRNA) profile and bioinformatics of patients with spleen-deficiency syndrome (SDS) and explore pathogenesis of SDS patients from miRNA levels, 10 patients with type 2 diabetes mellitus (T2DM), within which 5 patients were with SDS and the remaining were with blood stasis syndrome (BSS), and 5 healthy volunteers were recruited. Serum miRNA profiles of SDS patients were identified by quantitative PCR array. Target prediction and functional annotation for miRNAs were performed by miRSystem database. The present study identified 11 candidate serum miRNAs for SDS patients, and their targets were significantly enriched in 18 KEGG pathways and 7 GO molecular functions. Those enriched KEGG pathways included (1) metabolisms of carbohydrate, protein, amino acid, and fatty acid, (2) signaling pathways of insulin, ErbB, chemokine, calcium, and type II diabetes mellitus, (3) invasions of bacterium,Escherichia coli, andShigella(Shigellosis), and (4) endocytosis and phagocytosis. Those enriched GO molecular functions were mainly involved in transcription regulation and regulation of metabolism. Our findings might elucidate the pathogenesis of SDS patients with disorders of substance metabolism and hypoimmunity from miRNA levels, as well as providing some miRNA biomarkers for clinical syndrome differentiation of SDS.

scholarly journals Effect of ‘hand and foot acupuncture with twelve needles’ on hemiplegia patients with ‘qi deficiency and blood stasis’ syndrome in the convalescent stage of Ischaemic stroke: study protocol for a randomised controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Wei-Hao Fang ◽  
Gui-Ling Wang ◽  
Qiang Liu ◽  
Xiao Ding ◽  
Zhen-Yao Wang ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Controlled Trial ◽  
Blood Stasis ◽  
Blood Stasis Syndrome ◽  
Controlled Clinical Trial ◽  
Link Type ◽  
Stroke Study ◽  
Group A ◽  
Randomised Controlled ◽  
Convalescent Stage

Abstract Background Hemiplegia is a common sequela after stroke, and acupuncture is one of the most common physical therapies used to treat hemiplegia during the recovery stage after ischaemic stroke. ‘Hand and foot acupuncture with twelve needles’ is an acupuncture treatment performed after stroke. The principal objective of this study is to assess the efficacy and safety of ‘hand and foot acupuncture with twelve needles’ for hemiplegia in the convalescent stage of ischaemic stroke. Methods This is the protocol for a randomised, controlled clinical trial with two groups: a ‘hand and foot acupuncture with twelve needles’ group and a routine acupuncture group. A total of 208 participants will be randomly assigned to two different groups in a 1:1 ratio and will undergo conventional rehabilitation. Limb function will be evaluated by the simplified Fugl-Meyer assessment scale, Barthel Index, modified Ashworth scale and National Institute of Health stroke scale. The participants will be evaluated at baseline (on the day of enrolment) and followed up at 2 weeks, 1 month, 2 months and 3 months after enrolment. Discussion The results of this study will provide evidence on the effectiveness of ‘hand and foot acupuncture with twelve needles’ in the treatment of limb dysfunction that can be used for future evaluations. Trial registration Chictr.org.cnChiCTR1900021774. Registered on 8 March 2019

scholarly journals Efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina (Qi stagnation and blood stasis syndrome): study protocol of a randomized, double-blind, placebo-controlled, multi-center clinical trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xiaofen Ruan ◽  
Yiping Li ◽  
Yuanlong Sun ◽  
Meijun Jia ◽  
Xiaowen Xu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Research ◽  
Stable Angina ◽  
Conventional Therapy ◽  
Blood Stasis ◽  
Chronic Stable Angina ◽  
Blood Stasis Syndrome ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Qi Stagnation

Abstract Background Coronary heart disease (CHD) has become one of the biggest health problems in the world. Stable angina is a common clinical type of CHD with poor prognosis and high mortality. Although there are various interventions for stable angina, none of them can significantly reduce mortality. Both basic and clinical research have shown that Suxiao Jiuxin Pill (SJP) can relieve the symptoms of angina pectoris and improve the clinical efficacy, but there is a lack of high-quality clinical research to provide research-based evidence. We design a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of SJP for stable angina. Methods/design This is a prospective, randomized, double-blind, placebo-controlled, and multicenter trial. The trial will enroll 324 participants with chronic stable angina (Qi Stagnation and Blood Stasis syndrome). All participants will have received the conventional therapy of chronic stable angina. Participants will be randomized into two groups, conventional therapy plus SJP group and conventional therapy plus placebo group. Eligible participants will receive either SJP or placebo (five pills administered orally, three times daily) in addition to conventional treatment for 24 weeks. The primary outcomes are the symptom improvement rate of angina from baseline to 4 weeks after inclusion and major adverse cardiovascular events (MACE). The secondary outcomes are angina classification (CCS), improvement of traditional Chinese medicine (TCM) syndromes, Seattle Angina Scale score, the dosage of emergency drugs and the stopping rate, and electrocardiogram (EKG) efficacy. Adverse events will be monitored throughout the trial. Discussion Integrated traditional Chinese and Western Medicine is commonly used for angina in China. This study will evaluate the clinical effectiveness and safety of SJP for angina. The results of the trial will provide high-level clinical research-based evidence for the application of SJP instable angina. Trial registration This study protocol was registered on 14 March 2019. The registration number is ChiCTR1900021876 on the Chinese Clinical Trial Registry.

Sign in / Sign up

Export Citation Format

Share Document